Sampatrilat (UK-81252) is used in research related to chronic heart failure and blood pressure regulation; it reduces mortality, improves survival rate and hemodynamic function in rats with coronary artery ligation (CAL); it attenuates CAL-induced increases in left ventricular end-diastolic pressure, heart weight, and collagen content in the viable left ventricle.